Codexis Management
Management criteria checks 1/4
Codexis' CEO is Stephen Dilly, appointed in Aug 2022, has a tenure of 1.58 years. total yearly compensation is $5.89M, comprised of 4.7% salary and 95.3% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth $634.75K. The average tenure of the management team and the board of directors is 1.6 years and 3.3 years respectively.
Key information
Stephen Dilly
Chief executive officer
US$5.9m
Total compensation
CEO salary percentage | 4.7% |
CEO tenure | 1.6yrs |
CEO ownership | 0.3% |
Management average tenure | 1.6yrs |
Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story
Dec 20What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?
Dec 19Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?
Nov 15Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S
Jun 28Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)
Jun 07At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?
May 09Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts
Feb 27We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn
Feb 25Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?
Nov 05Codexis appoints Kevin Norrett as chief operating officer
Oct 03We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth
Aug 23Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%
Jul 28Codexis: Profitability, Return On Capital Are Persistent Headwinds Looking Ahead
Jul 27Codexis gets new executive chief
Jul 18Are Investors Undervaluing Codexis, Inc. (NASDAQ:CDXS) By 35%?
Jul 06Why Codexis, Inc. (NASDAQ:CDXS) Could Be Worth Watching
May 10Codexis: A Company Rooting Itself In A Blossoming Market
Apr 18We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn
Apr 09Does This Valuation Of Codexis, Inc. (NASDAQ:CDXS) Imply Investors Are Overpaying?
Mar 14CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$76m |
Sep 30 2023 | n/a | n/a | -US$82m |
Jun 30 2023 | n/a | n/a | -US$57m |
Mar 31 2023 | n/a | n/a | -US$48m |
Dec 31 2022 | US$6m | US$279k | -US$34m |
Sep 30 2022 | n/a | n/a | -US$31m |
Jun 30 2022 | n/a | n/a | -US$19m |
Mar 31 2022 | n/a | n/a | -US$21m |
Dec 31 2021 | US$175k | n/a | -US$21m |
Sep 30 2021 | n/a | n/a | -US$15m |
Jun 30 2021 | n/a | n/a | -US$23m |
Mar 31 2021 | n/a | n/a | -US$25m |
Dec 31 2020 | US$241k | n/a | -US$24m |
Compensation vs Market: Stephen's total compensation ($USD5.89M) is above average for companies of similar size in the US market ($USD1.47M).
Compensation vs Earnings: Stephen's compensation has increased whilst the company is unprofitable.
CEO
Stephen Dilly (63 yo)
1.6yrs
Tenure
US$5,893,151
Compensation
Dr. Stephen George Dilly, M.B.B.S, Ph D., serves as Independent Director of Codexis, Inc. since June 16, 2020. He serves as Director at ImmunoMolecular Therapeutics, Inc since February 2020.Dr. Dilly serv...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 1.6yrs | US$5.89m | 0.26% $ 634.7k | |
Chief Operating Officer | 1.4yrs | US$2.62m | 0.21% $ 525.1k | |
Chief Legal and Compliance Officer | 1.3yrs | US$2.18m | 0.049% $ 121.4k | |
Chief Financial Officer | 1.2yrs | no data | 0.18% $ 430.8k | |
Director of Investor Relations | no data | no data | no data | |
Senior VP & Head of Human Resources | 2.3yrs | no data | no data | |
Senior Vice President of Research | 3.8yrs | no data | no data | |
Senior Vice President of Pharmaceutical Development | 3.7yrs | no data | no data |
1.6yrs
Average Tenure
51yo
Average Age
Experienced Management: CDXS's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 3.8yrs | US$5.89m | 0.26% $ 634.7k | |
Independent Director | 1.3yrs | US$203.47k | 0.10% $ 253.0k | |
Member of Strategic Advisory Board | less than a year | no data | no data | |
Independent Director | 8yrs | US$194.99k | 0.18% $ 429.9k | |
Independent Director | 16.3yrs | US$189.99k | 0.11% $ 268.0k | |
Independent Director | 1.4yrs | US$217.96k | 0.094% $ 230.2k | |
Member of Strategic Advisory Board | less than a year | US$1.02m | no data | |
Member of Strategic Advisory Board | less than a year | no data | no data | |
Independent Chairman | 13.1yrs | US$221.66k | 0.28% $ 675.2k | |
Independent Director | 3.8yrs | US$189.99k | 0.098% $ 239.3k | |
Independent Director | 3.6yrs | US$177.01k | 0.094% $ 231.1k | |
Independent Director | 3.1yrs | US$170.21k | 0.082% $ 202.2k |
3.3yrs
Average Tenure
62yo
Average Age
Experienced Board: CDXS's board of directors are considered experienced (3.3 years average tenure).